Mylan
Mylan looks to muscle in on Allergan’s Botox territory
March 1, 2018Sales and Marketing Botox, Mylan, Revance Therapeutics, biotech, drugs, epipen, pharma, pharmaceutical
Mylan announced, alongside its financials, that it had signed a global collaboration and licensing agreement with Revance Therapeutics to partner …
Allergan’s patent gamble fails
February 27, 2018Manufacturing and Production, Medical Communications Allergan, Mylan, biotech, drugs, patent, pharma, pharmaceutical
Allergan’s patent deal with the Saint Regis Mohawk Tribe, in an attempt to protect itself from an inter partes review …
EMA committee recommends seven therapies from Roche, GSK, MSD and more
January 29, 2018Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …
Mylan and Biocon biosimilar approval expands to Brazil
January 2, 2018Manufacturing and Production, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, pharma, pharmaceutical
Since Mylan and Biocon managed to gain US FDA approval for its Herceptin (Trastuzumab) biosimilar, it has forged ahead in …
Mylan’s Ogivri becomes first and only FDA-approved Herceptin biosimilar
December 4, 2017Sales and Marketing Biocon, Cancer, FDA, Herceptin, Mylan, Roche, biosimilar, pharma
The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …
FDA unveils guidelines to help generic medical device versions reach the market
November 28, 2017Research and Development, Sales and Marketing FDA, Mylan, Scott Gottlieb, auto injector, auto-injector, epipen, pharma
The scandal surrounding Mylan’s price-hiking of its flagship EpiPen epinephrine auto-injector was the news of last summer, continuing to grab …
Mylan to withdraw from Tel Aviv Stock Exchange
November 13, 2017Sales and Marketing Mylan, TASE, pharma
US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement …
Teva’s woes continue, as shares sink to 17-year low on Q3 results
November 2, 2017Medical Communications Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Spare a thought for Kare Schultz, he agreed to take on the position of CEO at Teva at the start …
Allergan ready to take a loss by selling Teva shares
November 2, 2017Sales and Marketing Allergan, Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Allergan sold its generic business to Teva back in August 2016 for a sum of $33 billion and 100 million …
CEO and President implicated as price-fixing probe widens
November 1, 2017Research and Development, Sales and Marketing Mylan, Teva, biotech, drugs, pharma, pharmaceutical
A group of states, 45 members-strong, has expanded its probe into the generics pharmaceutical industry by expanding its case to …
Sanofi launches patent infringement lawsuit against Mylan over diabetes pen
October 25, 2017Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma
Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …
Mylan and Biocon Neulasta biosimilar knocked back by FDA
October 11, 2017Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta, biotech, drugs, pharma, pharmaceutical
Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the …
Mylan receives shock approval of Teva blockbuster
October 5, 2017Sales and Marketing Copaxone, Mylan, Teva, biotech, drugs, pharma, pharmaceutical
Mylan had been knocked back by the FDA in its quest to have its generic version of Copaxone approved earlier …
Top Ten most popular articles on Pharmafile.com this week
September 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten
It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …
Indivior reaches settlement with Mylan over patent dispute
September 25, 2017Sales and Marketing Mylan, indivior, patent, pharma, pharmaceutical, suboxone
Indivior has ended a patent dispute with Mylan concerning its heroin addiction therapy Suboxone (buprenorphine and naloxone) sublingual film by …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
